ClinicalTrials.gg
RecruitingNCT07600541AITXUpdated May 20, 2026

Perceptions of Kidney Transplant Recipients Regarding the Role of Artificial Intelligence in Medicine

An observational study in Kidney Transplant, sponsored by Paris Translational Research Center for Organ Transplantation. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Paris Translational Research Center for Organ Transplantation · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Study summary

The AITX study is an international, multicenter survey exploring how kidney transplant recipients perceive artificial intelligence (AI) in medicine and, specifically, a system that predicts graft loss risk. Through an open-ended online questionnaire distributed across transplant centers and patient associations in France and the United States, the study captures patients' expectations, concerns, and the perceived impact of AI-driven prediction on their daily lives. Responses are analyzed using large language models (LLMs) with systematic human verification. The study aims to ensure that the deployment of AI in transplantation is ethical, transparent, and patient-centered.

Read the detailed description

# Study Summary

## Background

Kidney transplantation is currently the gold standard treatment for end-stage renal disease, with over 170,000 transplants performed each year worldwide. Despite major advances in short-term survival, long-term graft survival remains limited: approximately 40% of patients return to dialysis within 10 to 15 years following transplantation.

In recent years, artificial intelligence (AI) has emerged as a promising tool for predicting graft outcomes and supporting clinical decision-making. The iBox system, developed by the Paris Institute for Transplantation and Organ Regeneration, calculates a personalized probability of graft loss up to ten years after evaluation of the kidney transplant recipient.

This algorithm has been validated internationally across multiple cohorts and clinical trials, outperforms clinicians in predicting risk, and was qualified by the European Medicines Agency as an endpoint for clinical trials in 2022.

However, while the clinical value of the iBox and similar predictive tools is well documented, patient perceptions remain largely unexplored. Understanding how kidney transplant recipients perceive the prediction of their individual risk of graft loss (in terms of usefulness, acceptability, fears, or impact on their daily life), as well as their broader views on the role of artificial intelligence in medicine - including their hopes, expectations, and concerns about its deployment - is essential to ensure an ethical, transparent, and truly patient-centered implementation.

## Study period

January 2026: Distribution of the questionnaire to the collaborating transplant centers and patient associations. February 2026: Data collection and management. April 2026: Analysis of results. June 2026: Presentation and discussion of results with the various participating centers/associations. September 2026: Publication.

## Sample size

The questionnaire will be distributed to a sample of between 10,000 and 20,000 kidney transplant recipients. Based on response rates observed in comparable studies using patient questionnaires, an estimated response rate of 10% to 15% is expected, which would yield a sufficient volume of responses to ensure statistical robustness and diversity of represented profiles.

## Study type

Cross-sectional, international, and multicenter survey, conducted via an anonymized online questionnaire. The study adopts a mixed-methods approach, combining qualitative and quantitative analysis of responses. No medical or biological data will be used, nor will data collected during clinical care be reused.

  • Questionnaire development:** The questionnaire was developed based on a review of the existing literature on patient perceptions of artificial intelligence and predictive medicine. An initial version of the questionnaire was developed and tested with four French patients. After adjustments, a bilingual translation was carried out by French-speaking and English-speaking collaborators. The final questionnaire was then shared with American patients for linguistic and cultural validation (**questionnaire presented in the appendix of this document**).
  • Questionnaire distribution:** Distribution will be carried out through partner patient associations and collaborating transplant centers in France and the United States. The questionnaire will be distributed via a secure and anonymized REDCap platform, hosted on institutional servers compliant with data protection standards (GDPR). Participants will receive a unique link allowing them to access the online questionnaire directly. Participants will be able to respond at their own pace and discontinue their participation at any time without justification or consequence.
  • Data analysis:** The collected responses will be analyzed using a quantitative approach. Qualitative analyses will rely on thematic analysis assisted by large language models (LLMs). These models will automatically extract recurring themes, associated emotions, and nuances of perception in the free-text responses, using a standardized methodology developed by the investigators. This type of LLM-based thematic analysis was already successfully conducted in the investigators' group. To ensure reliability and scientific rigor, a systematic manual verification will be performed on a representative sub-sample of responses. This independent review will compare human and automated coding and refine the thematic categories.

    • Data collected

      • Age
      • Sex
      • Year of last transplant
      • Country of last transplant
      • Transplant follow-up center
      • Transplant rank
      • Current occupation or last occupation held
      • Perceptions of the role of AI in medicine
      • Perceptions regarding a graft loss risk prediction system
    • Data flow

Data will be collected via the REDCap platform (HDS-certified hosting, GDPR-compliant). The questionnaire is anonymous: no nominative or identifiable medical data will be collected. Each participant will receive a unique link generating an untraceable alphanumeric identifier. Data will be transferred from REDCap and stored in encrypted form on institutional servers. Access will be strictly limited to the project investigators (Marc Raynaud, Alexandre Loupy) and the data manager (Thibaut Thalamas) via secure authentication. Data analyses will be performed on an internal environment using R. Fully anonymized datasets may be archived for secondary research or scientific replicability purposes.

## Participant information

Participants will be contacted by email via their follow-up center, using contact databases already existing at these centers. The invitation message will briefly present the study and its sponsor, the Paris Institute for Transplantation and Organ Regeneration, as well as the responsible researchers. It will also contain an information notice outlining the study objectives, confidentiality procedures, and a direct link to the online questionnaire hosted on REDCap. Participation will be entirely voluntary, with no impact on medical follow-up or the relationship with the transplant team.

02

Conditions studied

  • Kidney Transplant

Keywords

  • artificial intelligence
  • survey
03

In context

Lead sponsor

Paris Translational Research Center for Organ Transplantation is the lead sponsor of 31 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study targets adult kidney transplant recipients (≥18 years), fluent in French or English, and able to provide electronic consent. Patients with severe cognitive impairment preventing comprehension or technical inability to access the online questionnaire are excluded. Participants are recruited through transplant centers and patient associations in France and the United States. The questionnaire will be distributed to an estimated 10,000-20,000 patients, with an expected response rate of 10-15%

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years

    • Fluency in French or English
    • Electronic consent given

Exclusion criteria

  • Severe cognitive impairment preventing comprehension

    • Technical inability to access the questionnaire
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Vita move

    Association of transplant recipients

  • France rein pays de la loire

    Association of patients with kidney disease

  • France rein île de france

    Association of patients with kidney disease

  • France rein nord pas de calais

    Association of patients with kidney disease

  • Saint-Louis hospital

    Hospital

  • Nice Pasteur

    Hospital

  • Marseille hospital

    hospital

  • Lille

    hospital

  • The voice of the patient

    Association of patients with kidney disease

  • Utah university

    hospital

  • Mayo Clinic jacksonville

    hospital

06

What researchers measure

Primary outcomes

  1. Perceptions of patients about AI

    Perceptions of kidney transplant recipients regarding the use of artificial intelligence, assessed with a questionnaire

    Time frame: Baseline (corresponding to questionnaire administration)

Secondary outcomes

  1. Perceptions of patients about the use of a graft failure prediction system

    This study aims to explore the perceptions of kidney transplant recipients regarding the use of a graft loss risk prediction system, assessed with a questionnaire

    Time frame: Baseline (corresponding to questionnaire administration)

07

Study locations

2 of 2 sites recruiting
  • Le flambeau de la vie
    Paris, Île-de-France Region 75015, France
    Recruiting
  • Nice Pasteur
    Paris, Île-de-France Region 75015, France
    Recruiting
08

References and documents

Publications

  • Young AT, Amara D, Bhattacharya A, Wei ML. Patient and general public attitudes towards clinical artificial intelligence: a mixed methods systematic review. Lancet Digit Health. 2021 Sep;3(9):e599-e611. doi: 10.1016/S2589-7500(21)00132-1. PubMed 34446266 ↗
  • https://osf.io/preprints/psyarxiv/pnx9e_v1
  • Fritsch SJ, Blankenheim A, Wahl A, Hetfeld P, Maassen O, Deffge S, Kunze J, Rossaint R, Riedel M, Marx G, Bickenbach J. Attitudes and perception of artificial intelligence in healthcare: A cross-sectional survey among patients. Digit Health. 2022 Aug 8;8:20552076221116772. doi: 10.1177/20552076221116772. eCollection 2022 Jan-Dec. PubMed 35983102 ↗
  • Erul E, Aktekin Y, Danisman FB, Gumustas SA, Aktekin BS, Yekeduz E, Urun Y. Perceptions, Attitudes, and Concerns on Artificial Intelligence Applications in Patients with Cancer. Cancer Control. 2025 Jan-Dec;32:10732748251343245. doi: 10.1177/10732748251343245. Epub 2025 May 23. PubMed 40407404 ↗
  • Divard G, Raynaud M, Tatapudi VS, Abdalla B, Bailly E, Assayag M, Binois Y, Cohen R, Zhang H, Ulloa C, Linhares K, Tedesco HS, Legendre C, Jouven X, Montgomery RA, Lefaucheur C, Aubert O, Loupy A. Comparison of artificial intelligence and human-based prediction and stratification of the risk of long-term kidney allograft failure. Commun Med (Lond). 2022 Nov 23;2(1):150. doi: 10.1038/s43856-022-00201-9. PubMed 36418380 ↗
  • Truchot A, Raynaud M, Helantera I, Aubert O, Kamar N, Divard G, Astor B, Legendre C, Hertig A, Buchler M, Crespo M, Akalin E, Pujol GS, Ribeiro de Castro MC, Matas AJ, Ulloa C, Jordan SC, Huang E, Juric I, Basic-Jukic N, Coemans M, Naesens M, Friedewald JJ, Silva HT Jr, Lefaucheur C, Segev DL, Collins GS, Loupy A. Competing and Noncompeting Risk Models for Predicting Kidney Allograft Failure. J Am Soc Nephrol. 2025 Apr 1;36(4):688-701. doi: 10.1681/ASN.0000000517. Epub 2024 Oct 16. PubMed 40168162 ↗
  • Lombardi Y, Raynaud M, Schatzl M, Mayer KA, Diebold M, Patel UD, Schrezenmeier E, Akifova A, Budde K, Loupy A, Bohmig GA. Estimating the efficacy of felzartamab to treat antibody-mediated rejection using the iBox prognostication system. Am J Transplant. 2025 May;25(5):1130-1132. doi: 10.1016/j.ajt.2024.12.004. Epub 2024 Dec 12. No abstract available. PubMed 39674514 ↗
  • Loupy A, Preka E, Chen X, Wang H, He J, Zhang K. Reshaping transplantation with AI, emerging technologies and xenotransplantation. Nat Med. 2025 Jul;31(7):2161-2173. doi: 10.1038/s41591-025-03801-9. Epub 2025 Jul 14. PubMed 40659768 ↗
  • Raynaud M, Aubert O, Divard G, Reese PP, Kamar N, Yoo D, Chin CS, Bailly E, Buchler M, Ladriere M, Le Quintrec M, Delahousse M, Juric I, Basic-Jukic N, Crespo M, Silva HT Jr, Linhares K, Ribeiro de Castro MC, Soler Pujol G, Empana JP, Ulloa C, Akalin E, Bohmig G, Huang E, Stegall MD, Bentall AJ, Montgomery RA, Jordan SC, Oberbauer R, Segev DL, Friedewald JJ, Jouven X, Legendre C, Lefaucheur C, Loupy A. Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study. Lancet Digit Health. 2021 Dec;3(12):e795-e805. doi: 10.1016/S2589-7500(21)00209-0. Epub 2021 Oct 28. PubMed 34756569 ↗
  • Hart A, Gustafson SK, Wey A, Salkowski N, Snyder JJ, Kasiske BL, Israni AK. The association between loss of Medicare, immunosuppressive medication use, and kidney transplant outcomes. Am J Transplant. 2019 Jul;19(7):1964-1971. doi: 10.1111/ajt.15293. Epub 2019 Mar 5. PubMed 30838768 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — This is part of the investigators' protocol: as these data will reflect the views of the patients, the investigators prefer to keep them confidential.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Sep 2026, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
May 20, 2026
StartActual
Apr 15, 2026
Primary completionEst.
Sep 30, 2026
CompletionEst.
Dec 30, 2026
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07600541
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Responsible party
Marc Raynaud (Scientific leader, Paris Translational Research Center for Organ Transplantation) — Principal investigator
First posted
May 20, 2026
Start date
Apr 15, 2026
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
May 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion